Apparent deficiencies in the phase III data for Seres Therapeutics, SER-109: a closer inspection of the data prior to a decision by the FDA expert committee.
Bullari, Mikaela, Jonathan Darauay, Khadijah Edhi, Karen Elizondo, Leen Elyas, Hermela Gebregzabher, Vanessa Griffin, et al. 2020. “Apparent Deficiencies in the Phase III Data for Seres Therapeutics, SER-109: A Closer Inspection of the Data Prior to a Decision by the FDA Expert Committee.” Journal of High School Science, August.